Literature DB >> 15944309

Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans.

Johanna Rivera1, Arturo Casadevall.   

Abstract

The protective efficacy of mAbs to Cryptococcus neoformans glucuronoxylomannan depends on Ab isotype. Previous studies in A/JCr and C57BL/6J mice showed relative protective efficacy of IgG1, IgG2a >> IgG3. However, we now report that in C57BL/6J x 129/Sv mice, IgG3 is protective while IgG1 is not protective, with neither isotype being protective in 129/Sv mice. IgG1, IgG2a, and IgG3 had different effects on IFN-gamma expression in infected C57BL/6J x 129/Sv mice. IgG1-treated C57BL/6J x 129/Sv mice had significantly more pulmonary eosinophilia than IgG2a- and IgG3-treated C57BL/6J x 129/Sv mice. C. neoformans infection and Ab administration had different effects on FcgammaRI, FcgammaRII, and FcgammaRIII expression in C57BL/6J, 129/Sv, and C57BL/6J x 129/Sv mice. Our results indicate that the relative efficacy of Ab isotype function against C. neoformans is a function of the genetic background of the host and that IgG3-mediated protection in C57BL/6J x 129/Sv mice was associated with lower levels of IFN-gamma and fewer pulmonary eosinophils. The dependence of isotype efficacy on host genetics underscores a previously unsuspected complex relationship between the cellular and humoral arms of the adaptive immune response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944309     DOI: 10.4049/jimmunol.174.12.8017

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Antibody immunity and natural resistance to cryptococcosis.

Authors:  N Trevijano-Contador; L Pirofski
Journal:  Curr Trop Med Rep       Date:  2019-04-04

2.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 3.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

4.  The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.

Authors:  Oscar Zaragoza; Mauricio Alvarez; Andrew Telzak; Johanna Rivera; Arturo Casadevall
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

5.  The RGS protein Crg2 is required for establishment and progression of murine pulmonary cryptococcosis.

Authors:  Amy Whittington; Ping Wang
Journal:  Med Mycol       Date:  2010-09-06       Impact factor: 4.076

6.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection.

Authors:  Helene C Eisenman; Arturo Casadevall; Erin E McClelland
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

7.  Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Matthew S Marks; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

8.  Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.

Authors:  Loïc Guillot; Scott F Carroll; Robert Homer; Salman T Qureshi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

9.  Dependence of macrophage phagocytic efficacy on antibody concentration.

Authors:  Natasa Macura; Tong Zhang; Arturo Casadevall
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

10.  DAP12 Inhibits Pulmonary Immune Responses to Cryptococcus neoformans.

Authors:  Lena J Heung; Tobias M Hohl
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.